1) Mutation of the PC binding domain of EPCR results in viable mice (EPCR R84A/R84A ) that exhibit a procoagulant and pro-inflammatory phenotype when challenged.
Introduction
The protein C (PC) pathway plays a major role in inhibiting blood coagulation 1 . The pathway is initiated upon binding of thrombin to thrombomodulin (TM) on the surface of vascular endothelial cells. The thrombin-TM complex rapidly converts zymogen PC to its active form activated protein C (APC). APC generation is augmented by ∼20-fold in vivo by the endothelial protein C receptor (EPCR), a receptor which binds circulating PC and presents it to the thrombin-TM complex 2 . APC, in conjunction with its cofactor protein S, degrades coagulation cofactors Va and VIIIa, thereby attenuating thrombin generation. Congenital or acquired defects in components of the PC pathway are associated with an increased risk of venous thrombosis [3] [4] [5] In mice, EPCR gene disruption results in early embryonic lethality due to fibrin deposition and placental thrombosis 6 . During embryogenesis, EPCR is expressed primarily on trophoblast giant cells at the feto-maternal boundary 7 . Conditional EPCR knockout with specific deletion of EPCR in the developing embryo, but not on trophoblast giant cells, results in viable EPCR deficient mice (ProcrLox) with no evidence of spontaneous thrombosis 8 . EPCR has also been found to be highly expressed on hematopoietic stem cells (HSC) 9 , however the biological role for EPCR on HSCs is unclear since selective deletion of EPCR on hematopoietic cells has minimal effects on systemic PC activation 10 .
In addition to augmenting PC activation, EPCR also mediates the anti-inflammatory, anti-apoptotic, and endothelial barrier protective effects of APC 11, 12 . On endothelial cells, the receptors required for both PC activation (TM and EPCR) and APC-mediated cellular signaling (EPCR and protease activated receptor-1(PAR-1)) pathways are colocalized in lipid rafts 13 . EPCR serves as a co-receptor for APC-mediated cleavage of PAR-1 14 . Occupancy of
For personal use only. on January 1, 2018. by guest www.bloodjournal.org From EPCR by PC/APC switches the specificity of PAR-1-dependent signaling from a permeabilityenhancing to a barrier-protective response 15 . APC-mediated PAR-1 cytoprotective signaling requires β -arrestin recruitment and activation of the disheveled-2 (Dvl-2) scaffold 16 . In vivo, overexpression of EPCR on endothelial cells protects mice against thrombotic or septic challenge 17 and inhibition of PC binding to EPCR in baboons converts the response of sublethal concentrations of Escherichia coli into a lethal response 17, 18 .
Currently, there are no animal models to study the biological role of EPCR independent of its interaction with PC/APC. In this study, we generated a point mutation knock-in mouse model harboring a variant of EPCR (R84A) which lacks ability to bind PC/APC. Our findings suggest that EPCR not only regulates coagulation and inflammation, but also plays an important role in hematopoiesis.
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Materials and Methods

Generation of WT and R84A mEPCR stable cell lines
Construction and mutagenesis of murine EPCR (mEPCR) was done as previously described 19 . Human embryonic kidney cells (HEK293) were transfected with pcDNA3.1( -) vectors containing WT mEPCR or R84A mEPCR cDNAs using Effectene transfection reagent (Qiagen, Valencia, CA). After 2 weeks of drug selection (400 µg/mL of G418) drug-resistant colonies were isolated, and expression of cell surface WT or R84A mEPCR was assessed using a FACSCalibur™ flow cytometer (Becton Dickinson, Franklin Lakes, NJ).
Determination of the affinity of Fl-APC for WT mEPCR and R84A mEPCR
To assess the binding of murine APC to WT or R84A mEPCR, murine APC (kindly provided by Dr. Charles Esmon, Oklahoma Medical Research Foundation, Oklahoma City, OK) was labeled at the active site with fluorescein (Fl) (Haematological Technologies, Essex Junction, VT) as previously described 19 . HEK293 cells stably transfected with WT or R84A mEPCR were incubated with increasing concentrations of Fl-APC at 4 °C for 15 min in the dark.
Bound Fl-APC was detected on the fluorescence-1 channel on a FACSCalibur flow cytometer.
Values for Kd were determined by fitting binding isotherms with a hyperbolic equation using the TableCurve program (Jandel Scientific, San Rafael, CA).
Generation of homozygous R84A EPCR knock-in mice
All animal care and experimental procedures were approved by the McMaster University
Research Ethics Board. In collaboration with GenOway (France), the EPCR R84A/R84A knock-in mouse was generated using the following strategy: the gene targeting vector consisted of exons 1-3, where exon 2 contained the desired R84A point mutation. The targeting vector was introduced into mouse embryonic stem cells of the 129Sv/Pas background and homologous ), and backcrossed 3 generations with C57BL/6 mice.
Hematological analysis of murine blood
Blood was collected via cardiac puncture into 3.2% sodium citrate and a complete blood count was done using the Hemavet 950FS hematology cell analyzer (Drew Scientific, Waterbury CT).
Bone marrow transplantation
Recipient mice (10-12 weeks old) were exposed to 14Gy of γ -irradiation from a 137 Cs source using a Gammacel 3000 small animal irradiator. Bone marrow (BM) prepared from the tibias and femurs of donor mice was injected via the retro-orbital sinus. Mice were allowed to recover for four weeks before blood was collected and DNA isolated using QIAamp DNA Blood 
Colony-forming cell assays
Isolated spleen, bone marrow, and peripheral blood cells from mice were added to methylcellulose complete media and plated on 35mm dishes as described by the manufacturer (R&D Systems, Minneapolis, MN). Plated cells were incubated for 8 days in a humidified incubator at 37°C and 5% CO 2 . Colonies were identified and enumerated using gridded scoring dishes on an inverted light microscope.
Immunoblotting of tissue lysates
Mouse organs (heart, kidney, liver, lung and spleen) were collected and snap frozen in liquid N 2. Tissue lysates were prepared by incubating tissues in lysis buffer (Millipore, Billerica,
For personal use only. on January 1, 2018. by guest www.bloodjournal.org From MA), followed by homogenization of tissues. Homogenized tissue was spun down at 5500 x g for 20 minutes at room temperature and the supernatant was collected. SDS-PAGE of the tissue lysates was performed and protein was transferred onto a nitrocellulose membrane.
Immunoblotting was performed using a polyclonal rabbit anti-EPCR antibody (Clone G-20)
(Santa Cruz Biotechnology, Dallas, TX ) and HRP-conjugated anti-rabbit antibody (Bio-Rad, Mississauga, ON).
Immunohistochemistry and immunofluorescence
Mouse tissues were collected and snap frozen in dry ice with optimal cutting temperature embedding medium and stored at -70°C. Tissues were sectioned (8 To collect tissues for fibrin staining of FXa/PCPS challenged mice, WT and EPCR R84A/R84A mice were exsanguinated by cardiac puncture, and slowly perfused with 20 mL of 0.9% NaCl containing 200 U/mL of heparin, followed by fixation of tissues in 10% formalin.
Tissues were dissected, paraffin embedded and processed for sectioning. Tissue sections (5 μ m thick) were stained with a polyclonal rabbit anti-human fibrin antibody (Dako, Glostrup Denmark). The anti-fibrin antibody was detected by incubation with an alkaline phosphatase goat anti-rabbit secondary antibody, followed by incubation with Vector Red, a substrate that generates a bright red product (Vector laboratories, Burlingame, CA). Samples were examined by an Olympus BX41 fluorescent microscope and images collected using an Olympus DP72
For personal use only. on January 1, 2018. by guest www.bloodjournal.org From camera (Olympus Corporation, Tokyo, Japan). For quantification of fibrin, the mean fluorescence intensity (MFI) of 10 images per experimental sample was measured using Slidebook software and corrected for the autofluorescence of the tissue by subtracting the MFI of the negative control. To quantitate the amount of red pulp/white pulp in the spleen of WT and R84A mice, the total spleen area and white pulp area of H&E stained splenic sections was calculated using ImageJ software. The area of the white pulp and red pulp was then expressed as a percent of total spleen area.
Thrombotic challenge
To determine the effect of the EPCR R84A mutation on PC activation in vivo, 
Analysis of murine PC, APC, TAT and IL-6 levels
Mouse PC and APC was assayed as described previously. 17 Mouse thrombinantithrombin (TAT) complexes were measured using the Enzygnost TAT kit as described by the manufacturer (Siemens, Munich, Germany). Mouse IL-6 antigen was measured using the Quantikine IL-6 ELISA kit as described by the manufacturer. (R&D Systems, Minneapolis, MN)
Statistics
Results are shown as the mean ± the standard error (SE . A P-value < 0.05 was considered to be statistically significant. . In contrast, R84A mEPCR binding to Fl-mAPC did not saturate even at FlmAPC concentrations of 500 nM, which is much higher than the circulating concentration of PC [~60 nM] ( Figure 1B ). These studies confirm that the R84A mEPCR variant is expressed on the cell surface but lacks the ability to bind to PC/APC. We are also able to confirm that Fl-mFVIIa and Fl-mFXa does not bind WT or R84A mEPCR (supplemental Figure 1) .
Generation of EPCR R84A/R84A mice
To study the biological role of EPCR in the absence of PC/APC binding in vivo we generated mice carrying a point mutation in EPCR (R84A). A targeting vector was designed to introduce an R84A point mutation in exon 2 of EPCR, floxed by two loxP sites and a neomycin cassette ( Figure 2A ). Mice homozygous for the EPCR R84A mutation were confirmed by PCR analysis ( Figure 2B ). Both EPCR R84A/R84A and EPCR WT/R84A mice had normal fertility and lifespans without apparent gross abnormalities.
For EPCR protein levels were similar in the heart, kidney, liver, lung, and spleen of WT and EPCR R84A/R84A mice ( Figure 3A) . Expression of EPCR by aortic endothelial cells was also unaffected by the R84A mutation ( Figure 3B ). Figure 4C ). Histological studies show that there is increased fibrin deposition in the lungs of EPCR R84A/R84A mice compared to WT mice ( Figure 4D and E). EPCR R84A/R84A mice also showed evidence of large intraventricular fibrin clots in the heart which were absent in EPCR WT/WT mice ( Figure 4F ).
LPS challenge in EPCR R84A/R84A mice
Next, we determined if mice harboring the R84A EPCR mutation exhibit a more proinflammatory phenotype when challenged with endotoxin. At 6 hours post-LPS injection, EPCR R84A/R84A mice had a ~3-fold increase in TAT levels ( Figure 5A ), and a ~2 fold decrease in circulating APC ( Figure 5B ) when compared to EPCR WT/WT mice. In LPS-challenged EPCR R84A/R84A mice, circulating IL-6 was significantly increased at 2 hours-post LPS injection when compared to EPCR WT/WT mice ( Figure 5C ). Since the lungs are a major site of neutrophil sequestration after LPS challenge, we also measured MPO activity (as a marker of neutrophil infiltration) in the lungs of EPCR WT/WT and EPCR R84A/R84A mice. MPO activity in lung homogenates of EPCR R84A/R84A mice was increased compared to EPCR WT/WT mice 24 hours after LPS injection ( Figure 5D ).
EPCR
R84A/R84A mice exhibit splenomegaly EPCR R84A/R84A mice developed a splenic disorder characterized by splenomegaly ( Figure   6A ). There was a significant increase in the splenic weight of EPCR R84A/R84A mice compared to 1 4 WT mice at 3 months of age and further increases in the splenic weight of EPCR R84A/R84A mice at 1 year ( Figure 6B ). Histological analysis of the spleen from EPCR R84A/R84A mice revealed an increased amount of red pulp (90.4 ± 0.5%) compared to EPCR WT/WT mice (69.2 ± 3.03%)
( Figure 6C and D) .
Hematological analysis of spleen, bone marrow and peripheral blood in EPCR R84A/R84A mice
Flow cytometric analysis of the spleen and BM was performed to further characterize the cell populations in EPCR R84A/R84A mice ( Figure 2) .
Bone Marrow Transplantation
To mice ( Figure 7B and C).
Discussion
The hemostatic balance is tightly regulated during embryonic development, especially at the feto-maternal interface. During development, maternal fibrinogen serves as a hemostatic agent (to assure that normal bleeding during development of vessels is controlled) and also as an anchor for placental-maternal attachment during embryonic development 23, 24 . The PC system has been shown to be essential for the maintenance of pregnancy. For example, TM-deficient mice do not survive beyond day E8.5, and death is caused by tissue factor-initiated coagulation at the feto-maternal interface 25 . Deletion of the EPCR gene in mice leads to an increase in fibrin deposition around the giant trophoblast cells at day E9.5 and embryonic lethality before day E10 6 . Using conditional knock-out strategies, it was shown that EPCR-deficient embryos with EPCR expression on placental giant trophoblast cells can develop normally 8 . These studies suggest that impaired PC activation at the feto-maternal interface leads to fibrin deposition and abortion of the embryo. However, we have now demonstrated that mice harboring a variant of EPCR that is deficient in PC binding ( Figure 1B ) and PC activation in vivo ( Figure 4A ) can reproduce normally and produce viable offspring.
If impairment in PC activation in the EPCR R84A/R84A mice does not lead to placental thrombosis and embryonic abortion, how is thrombin generation regulated at the feto-maternal interface? It has been demonstrated that EPCR deficiency is not embryonic lethal in genetically modified mice that express low TF (approximately 1% of normal), suggesting that decreased thrombin generation rescues EPCR-deficient embryos 8 . In this study, we found that the plasma level of PC was ~40% higher in EPCR R84A/R84 mice compared to WT mice, suggesting that introduction of the R84A mutation into EPCR results in a redistribution of intravascular PC 8, 17 .
We postulate that an increase in plasma PC levels may increase the PC activation rate by the 1 7 thrombin-TM complex. Although we did not detect measureable differences in plasma APC levels between WT and EPCR R84A/R84A mice ( mice have significant physiological consequences as a result of impaired PC binding to EPCR (Figure 4 and Figure 5 ). Similar to EPCR conditional knockout mice (ProcrLox), 8 EPCR R84A/R84A mice also have decreased platelet counts (Table 3) 8 . A decrease in platelet counts and increased extramedullary hematopoiesis may reflect a sub-acute coagulopathy resulting in hematopoietic compensation and enlargement of the spleen. However, enlargement of the spleen accompanied a by a decrease in total cell counts in the bone marrow of EPCR R84A/R84A mice, a phenotype that was not reported in EPCR ProcrLox mice, suggests that EPCR, independent of APC interaction may play an important role in maintaining hematopoietic homeostasis within the bone marrow. Despite decreased cell numbers in the bone marrow, and increased cell numbers in the spleen, percentages of B lymphocytes (B220+ cells), granulocyte progenitors (Gr-1+ cells) 1 8 megakaryocytes (CD41+), and HSPCs (LSK+) in the bone marrow and spleen were similar between EPCR WT/WT and EPCR R84A/R84A mice (Table 2) , and peripheral red and white blood cell counts remained normal in EPCR R84A/R84A mice (Table 3) suggesting that the spleen is able to support normal hematopoiesis.
EPCR is highly expressed on HSCs, and has been used to specifically identify HSCs in murine BM 9 . In mice, EPCR expression appears to be limited to HSCs, and is absent on circulating leukocytes 9, 27 . In support of this, deficiency of EPCR in hematopoietic cells does not impair the anticoagulant and anti-inflammatory responses in a mouse model of endotoxemia. 10 This is in contrast to humans, in which EPCR expression has been reported in neutrophils, monocytes, eosinophils, and natural killer cells [28] [29] [30] [31] . EPCR is also present within the BM stroma on endothelial cells, chondrocytes 32 , and osteoblasts 33 Coagulation regulators including tissue factor, thrombin, TM, and APC have been shown to be present in the small blood vessels of the bone marrow 34 and studies have revealed a role for the coagulation system in regulating hematopoiesis. Injection of thrombin into mice can induce rapid mobilization of HSPCs into the peripheral circulation, a process which is dependent on 1 9 thrombin activation of PAR-1 and secretion of stromal derived factor-1 34, 35 . . Six months post-BMT mice were sacrificed and total cell counts of BM (A), and spleen (B) were performed. Splenic weight was assessed (C). Data represents the mean ± SE, * p < 0.05, ** p <0.01, *** p < 0.001. n > 5 per group. 
